Timothy Barreiro, DO
Pulmonary Disease · Youngstown, OHNPI 1679670707
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,536 and has fallen 58.6% since, to $636 in 2025.
Across 143 payments — averaging $27.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$883
- Noah Medical Corporation$549
- AstraZeneca$478
- Sanofi$340
- Boehringer Ingelheim$273
- United Therapeutics Corporation$240
- plus $1K from 16 others
Across 9 payments — averaging $6701.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$60K
What the payments were for
- Travel & lodging$2266%
- Food & beverage$3,61990%
- Education$1564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 46 | $883 |
| Noah Medical Corporation | 7 | $549 |
| AstraZeneca | 19 | $478 |
| Sanofi | 7 | $340 |
| Boehringer Ingelheim | 15 | $273 |
| United Therapeutics Corporation | 3 | $240 |
| Pulmonx Corporation | 4 | $191 |
| Genentech USA, Inc. | 8 | $133 |
| Baxter Healthcare | 1 | $114 |
| Regeneron Healthcare Solutions, Inc. | 4 | $102 |
| Amgen | 1 | $99 |
| Intuitive Surgical | 1 | $98 |
| Novartis | 5 | $87 |
| Sunovion Pharmaceuticals Inc. | 6 | $81 |
| Insmed, Inc. | 1 | $75 |
| Johnson & Johnson | 4 | $60 |
| Mylan Specialty L.p. | 3 | $51 |
| Merck | 3 | $40 |
| Shire North American Group Inc | 2 | $29 |
| CSL Behring | 1 | $27 |
| Covidien LP | 1 | $27 |
| Grifols USA, LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,001 in reported general payments places this provider in the 65th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 310 | $241,747 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $119,377 |
| NucalaMepolizumab | 24 | $87,784 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $44,991 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $37,808 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $22,991 |
| Spiriva RespimatTiotropium Bromide | 44 | $22,629 |
| EliquisApixaban | 25 | $17,078 |
| Spiriva HandihalerTiotropium Bromide | 18 | $15,332 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $13,213 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $12,445 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $10,922 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 206 | $6,982 |
| DuleraMometasone/Formoterol | 19 | $6,908 |
| DalirespRoflumilast | 13 | $5,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $883 | $408,434490 claims |
| Grifols USA, LLCProlastin C | $23 | $119,37713 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Daliresp | $478 | $55,983106 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $273 | $35,84262 claims |
| MerckDulera | $40 | $6,90819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Youngstown
- Ashlee RussoYoungstown$61K
- Anthony BoulosYoungstown$24K
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.